Liraglutide: Research overview, identity, and laboratory handling guide

Acylated GLP-1 receptor agonist analogue studied in vitro for incretin-pathway and metabolic-signaling research. ≥99% HPLC. Research use only. This guide covers identity, published research context, procurement checks, and storage — RUO only, no clinical claims.

What Liraglutide is in published research

Liraglutide is a GLP-1(7-37) analogue with a single Arg34→Lys substitution and a γ-glutamyl C-16 palmitoyl modification at Lys-26. The acylation extends in vitro stability against DPP-IV and prolongs receptor occupancy in published research models. The peptide is widely studied in vitro for GLP-1 receptor binding, β-cell line signaling, and metabolic-pathway research.

Each lot is provided with HPLC purity at ≥99%, MS identity confirming both backbone sequence and acyl modification, and net peptide content. Labs comparing analogues commonly request the acyl-mass delta on the CoA — we file it by default.

Hold lyophilized vials sealed at -20 °C protected from light. Liraglutide reconstitutes more cleanly in slightly alkaline buffer than in neutral water; consult your assay protocol. Aliquot reconstituted stock before freezing.

CoA covers identity (MS), purity (HPLC), and net peptide content. Batch records by lot for compliance review.

The material class "GLP-1 receptor analogue (research)" helps procurement teams group Liraglutide with related reference peptides during comparative studies.

Sequence and identity

Liraglutide identity on the catalog: Common name: Liraglutide; Origin: GLP-1(7-37) analogue, C-16 fatty-acid acylation on Lys-26; Molecular formula: C172H265N43O51; Molecular weight: 3,751.20 g/mol; Appearance: White lyophilized powder; Purity (HPLC): ≥ 99%; Solubility: Soluble in slightly alkaline lab buffers. Copy these into receiving and LIMS before reconstitution.

Mechanisms studied in published research

Mechanism-focused research on Liraglutide is typically conducted in cell lines or biochemical preparations that express the relevant receptor or binding protein for its class.

Design controls that include scrambled-sequence or orthogonal-receptor negative controls when your protocol evaluates Liraglutide pharmacology in vitro.

Report effect sizes with lot number and CoA reference so results can be reproduced if the same Liraglutide SKU is reordered later.

Avoid extrapolating in vitro binding or signaling readouts to whole-organism outcomes; RUO materials are not qualified for clinical investigation.

Procurement and identity verification

Request the lot-specific CoA for Liraglutide at receipt. Verify SKU, variant size if applicable, and identity mass before the lot enters general storage.

Compare HPLC purity to your internal minimum for the peptide family. File chromatogram excerpts when your QMS requires raw data.

Enter net peptide content from the CoA into inventory before calculating molarity for Liraglutide working stocks.

Attach purchase order, packing list, and CoA in one audit folder per lot.

Storage and reconstitution

Store lyophilized Liraglutide sealed at -20 °C protected from light unless the CoA states otherwise.

Reconstitute with bacteriostatic water or a buffer validated for your assay pH. Aliquot to limit freeze-thaw.

For oxidation-sensitive sequences in Liraglutide, minimize open-vial time at room temperature during weighing.

See our lyophilized storage guide for institution-scale SOP examples and aliquot labeling conventions.

Comparative reference points

Researchers comparing Liraglutide with adjacent catalog references often evaluate the following SKUs in parallel plates:

Semaglutide (semaglutide) — compare identity table and CoA fields side by side.

Use matched reconstitution buffers and stock concentrations when running comparative binding or signaling assays.